Evaluating how cationic lipid affects mRNA-LNP physical properties and biodistribution

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Delivery Systems

Background:

• RNA therapeutics offer a promising strategy for diseases unresponsive to conventional treatments.
• Recent successes in mRNA vaccines and siRNA therapeutics highlight the potential of RNA-based medicines.
• Current limitations in mRNA-lipid nanoparticle (LNP) formulations include toxicity, stability, and biodistribution challenges.

Purpose of the Study:

• To develop and optimize novel lipid nanoparticle (LNP) formulations for enhanced in vivo messenger RNA (mRNA) delivery.
• To investigate a new cationic lipid molecule, IM21.7c, featuring an imidazolium polar head, for LNP formulation.
• To identify an optimal lipid composition for effective mRNA delivery and improved therapeutic outcomes.

Main Methods:

• A rational combinatorial approach was employed to screen and select optimal lipid formulations.
• The study focused on a novel cationic lipid, IM21.7c, incorporating an imidazolium polar head.
• Characterization of IM21.7c-based mRNA-LNPs included size, encapsulation efficiency, mRNA protection, release kinetics, and in vitro transfection.

Main Results:

• An optimal 5-lipid composition for in vivo mRNA delivery was identified.
• IM21.7c-based mRNA-LNPs, under 100 nm, demonstrated high encapsulation efficiency and protected mRNA from degradation.
• These LNPs exhibited sustained release kinetics for effective in vitro transfection and significantly different biodistribution compared to approved LNPs, with enhanced lung targeting.

Conclusions:

• The developed IM21.7c-based mRNA-LNPs represent a promising advancement in RNA delivery technology.
• The novel formulation exhibits favorable characteristics for mRNA therapeutics, including improved stability and targeted delivery.
• Further research is warranted to explore the full therapeutic potential of these new lipid molecules and formulations.